MIMRYLO's Launch: A New Era for PV Patients & A Win for Specialty Pharma

LOUISVILLE, KY – September 09, 2026 – In a move that signals both a clinical breakthrough and a strategic evolution in pharmaceutical distribution, Takeda Pharmaceuticals has selected Onco360® as a key partner for the launch of its new drug, MIMRYLO™ (rusfertide). This selection places the nation’s leading independent specialty pharmacy at the center of a highly controlled, 'ultra-narrow' network tasked with delivering a first-of-its-kind treatment for adults with polycythemia vera (PV), a rare and chronic blood cancer.

The partnership goes far beyond simple logistics. It represents a calculated decision by Takeda to embed its innovative therapy within a high-touch ecosystem, ensuring that patients grappling with a complex disease receive the specialized support necessary to achieve optimal outcomes. For Onco360, this affirms its growing influence as a critical intermediary in the oncology landscape, while for patients, it offers new hope for managing a difficult condition.

A New Horizon for Polycythemia Vera Patients

Polycythemia vera is a myeloproliferative neoplasm where the bone marrow overproduces red blood cells, thickening the blood and dramatically increasing the risk of life-threatening blood clots, which can lead to heart attacks and strokes. For decades, the standard of care has been a frustrating cycle of managing symptoms and risks. The primary goal is to keep the hematocrit—the proportion of red blood cells in the blood—below a critical 45% threshold.

For many of the estimated 100,000 Americans living with PV, treatment involves frequent phlebotomies, the clinical term for withdrawing blood. While effective in the short term, the procedure is burdensome and can lead to iron deficiency and its own set of symptoms. When phlebotomy is insufficient, patients often move to cytoreductive therapies like hydroxyurea, which can come with significant side effects and lose effectiveness over time. Patients often continue to suffer from debilitating symptoms like intense fatigue, maddening itchiness (pruritus), and an enlarged spleen, severely impacting their quality of life.

MIMRYLO enters this landscape as a fundamentally different approach. As a mimetic of hepcidin, a natural hormone, it works by blocking the iron transporter ferroportin. By limiting the iron available for red blood cell production, it directly addresses the overproduction at the source. The goal is to provide stable, long-term hematocrit control without the peaks and valleys of intermittent phlebotomy.

The drug's approval was based on the pivotal Phase 3 VERIFY study, which demonstrated its ability to help patients achieve the primary endpoint: the absence of phlebotomy eligibility. This suggests a future where patients can be freed from the regular need for blood withdrawals. While the treatment is not without side effects—injection site reactions were common (56%) and anemia was also noted (16%)—it represents a targeted mechanism that could transform the daily reality of living with PV.

The Strategic Rationale of Ultra-Narrow Distribution

Takeda’s decision to launch MIMRYLO through an 'ultra-narrow' specialty pharmacy network is a clear signal of a broader industry trend. For highly specialized, high-cost therapies targeting complex diseases, the traditional 'one-size-fits-all' distribution model is no longer sufficient. An ultra-narrow network involves partnering with a very small number of pharmacies chosen for their specific expertise and capabilities.

This strategy provides the manufacturer with significant advantages. First, it ensures quality control over the patient experience. A drug like MIMRYLO, administered via subcutaneous injection, requires patient education and ongoing support to ensure adherence and manage potential side effects. By concentrating distribution through an expert partner like Onco360, Takeda can be confident that patients are receiving consistent, high-quality clinical support. Second, it allows for better data collection and monitoring. A limited network provides clearer visibility into how a new drug is being used in the real world, which is invaluable for post-market surveillance and understanding patient outcomes.

For patients and physicians, this model presents a trade-off. While it limits their choice of pharmacy, it provides access to a depth of service that a standard retail pharmacy cannot offer. This includes proactive outreach, side-effect management, 24/7 clinical support, and crucial assistance in navigating the financial complexities of specialty drug reimbursement. In essence, the pharmacy becomes an integrated part of the patient's care team.

Onco360: The Critical Link in Complex Cancer Care

Onco360's selection for this partnership is no accident. Founded in 2003, the company has built its reputation as the nation’s largest independent oncology pharmacy by focusing exclusively on the intricate needs of cancer patients, oncologists, hospitals, and payers. This deep specialization makes it an ideal partner for a targeted oncology launch.

“We are proud to expand our partnership with Takeda and support the launch of MIMRYLO, a first-of-its kind rare blood cancer treatment for adults living with polycythemia vera,” said Benito Fernandez, Chief Commercial Officer at Onco360, in the company's announcement. “It is an opportunity to bring our unparalleled expertise to patients who rely on complex therapies and make a meaningful difference in their care.”

This expertise translates into tangible services for MIMRYLO patients. Onco360’s team of oncology-specialized pharmacists and nurses will be responsible for educating patients on proper injection techniques, monitoring for adverse events like injection site reactions, and developing strategies to promote long-term adherence. Furthermore, its role as a flagship brand of PharMerica Corporation provides the scale and resources necessary to manage a national rollout, while its URAC and ACHC accreditations signal a commitment to the highest standards of care.

This partnership solidifies Onco360’s position not merely as a dispenser of medicine, but as a vital component of the healthcare delivery system. It showcases how specialty pharmacies are increasingly becoming the strategic linchpin for manufacturers seeking to ensure their most innovative and complex therapies achieve their full clinical potential. The launch of MIMRYLO is therefore a growth signal on two fronts: a medical advance for a challenging disease and a powerful validation of the specialized, high-touch distribution model that is defining the future of pharmaceutical care.